Condition
Malignant Hydrothorax
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Unknown2
Clinical Trials (2)
Showing 2 of 2 trials
NCT03546452UnknownPrimary
A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC
NCT02579564Phase 3UnknownPrimary
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
Showing all 2 trials